Bromocriptine in Parkinson's disease: a study of cardiovascular effects.

AUTOR(ES)

Quinn, N

RESUMO

Blood pressure and pulse rate were studied in 20 Parkinsonian patients on no treatment, and during treatment with bromocriptine (mean dosage 148 mg/day) as the sole anti-Parkinsonian therapy. The drug was shown to reduce erect systolic and diastolic and supine systolic blood pressure and to increase erect pulse rate, in a predictable dose-dependent manner. The occurrence of episodes of significant postural hypotension was less predictable and was a transitory phenomenon in all patients. Peripheral dopamine receptor blockade with domperidone did not alter the findings, suggesting that the principal mechanism for these cardiovascular effects is a central dopaminergic one.

Documentos Relacionados

• Bromocriptine treatment in Parkinson's disease.
• Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
• Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
• Bromocriptine induced impotence in Parkinson's disease.
• Low-dose bromocriptine in Parkinson's disease.